SCHEMBL7126943

SCHEMBL7126943

O=C1Cc2cc(S(=O)(=O)Cc3cccc(OC(F)(F)F)c3)ccc2N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.46
GRIA1 P42261 1/20 0.45
CACNG8 Q8WXS5 1/20 0.45
GAA P10253 7/20 0.43
MAOB P27338 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 1/20 0.41
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 1/20 0.39
PKM P14618 1/20 0.39
DAO P14920 1/20 0.39
BRAF P15056 1/20 0.39
GLO1 Q04760 1/20 0.39
ULK1 O75385 1/20 0.39
PTK2 Q05397 1/20 0.39
PTK2B Q14289 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7126895 0.88 MAOB (0.50) GRIA1CACNG8GAAMAOBSMN1; SMN2
SCHEMBL7116190 0.86 PKM (0.51) GAAMAOBLMNAPKM
SCHEMBL7127344 0.84 GAA (0.58) KIF11GAASMN1; SMN2MAPTMEN1
SCHEMBL7125491 0.83 MAOB (0.54) KIF11GAAMAOBSMN1; SMN2MEN1
SCHEMBL7125782 0.82 PKM (0.48) GAAMAOBSMN1; SMN2MEN1KMT2A
SCHEMBL3249974 0.80 GAA (0.54) GAAMAOBSMN1; SMN2MEN1KMT2A
SCHEMBL7115706 0.80 IDO1 (0.50) GRIA1CACNG8GAAMAOBSMN1; SMN2
SCHEMBL7118444 0.80 GAA (0.56) GAAMAOBSMN1; SMN2MAPTMEN1
SCHEMBL688889 0.79 CES1 (0.56) KIF11GRIA1CACNG8GAAMAOB
SCHEMBL7122518 0.78 GAA (0.53) GAASMN1; SMN2MAPTKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 KIF11 3476/4885GRIA1 1149/4885CACNG8 2959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.